UnknownPhase 4

Effect of Tadalafil on Erectile Dysfunction Treatment and QOL Improvement Effect (by SF-12) in Andropause Patients With Erectile Dysfunction

South Korea40 participantsStarted 2016-07

Plain-language summary

Observational study to evaluate the effect of Tadalafil 5mg once daily on Erectile Dysfunction and QOL in Andropause patients with Erectile Dysfunction. Patients will be observed for 8weeks.

Who can participate

Age range35 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Above 35 years men
✓. Approving ADAM questionnaire and andropause patients with symptoms under contents
✓. Patient with Erectile Dysfunction above 6 months
✓. International Index of Erectile Function(IIEF-5) score under 21
✓. Voluntarily one want to treatment with Tadalafil 5 mg daily
✓. Voluntarily one agree this study and write informed consent

Exclusion criteria

✕. Persons who have taken PDE-5 inhibitor within last one month for Erectile Dysfunction
✕. Persons who taken testosterone treatment within last one month
✕. Persons who be history of Myocardiac infarction
✕. The history of taken organic nitrate drug
✕. The history of cardiovascular disease
✕. Persons who have degrative retinal disease including Pigmentary retinites
✕. Formerly persons who have one eye blindness by Artery anterior ischemic optic neuropathy with or without taking PDE5 inhibitor.
✕. Persons who use inhibitor or agonist drug f Hepatic cytochrome P4503A4

What they're measuring

Change on SF-12 Score from baseline to week 8

Timeframe: week 0 to week 8

Trial details

NCT IDNCT02943356

SponsorThe Catholic University of Korea

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-07

Contact for this trial

Keun-Sang Yum, M.D., PhD

8231-820-3179 yks6303@catholic.ac.kr

View on ClinicalTrials.gov More Erectile Dysfunction trials